

November 10, 2017  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Notice Concerning Non-operating Income

SymBio Pharmaceuticals Limited (“the Company”) announces accrued non-operating income for the third quarter of the fiscal year ended December 31, 2017 (from July 1, 2017 to September 30, 2017) as follows.

### 1. Details of Non-operating Income

The Company recorded a foreign exchange gain of 2,784 thousand yen under non-operating income for the third quarter of the fiscal year ended December 31, 2017 (from July 1, 2017 to September 30, 2017) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 27,266 thousand yen for the three months ended June 30, 2017, a total foreign exchange loss of 24,481 thousand yen was recorded in the Statements of Operations for the second quarter of the fiscal year ended December 31, 2017.

### 2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating income would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

### [Contact]

Investor Relations  
Tel: +81(0)3 5472 1125